Center for Substance Abuse Prevention; Advisory Committee; Drug Testing Advisory Board; Renewal, 43611 [2016-15815]

Download as PDF Federal Register / Vol. 81, No. 128 / Tuesday, July 5, 2016 / Notices Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6710 B Rockledge Drive, Room 2131D, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Sathasiva B. Kandasamy, Ph.D., Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710 B Rockledge Drive, Room 2131D, Bethesda, MD 20892, (301) 435–6680, skandasa@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: June 28, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–15731 Filed 7–1–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Complementary & Integrative Health; Notice of Closed Meeting sradovich on DSK3GDR082PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Complementary and Integrative Health Special Emphasis Panel; Clinical Research on Mind-Body Interventions. Date: July 29, 2016. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, DEMII, 401, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting). Contact Person: Hungyi Shau, Ph.D., Scientific Review Officer, National Center for Complementary and Integrative Health, National Institutes of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892, 301–480–9504, Hungyi.Shau@ nih.gov. VerDate Sep<11>2014 17:27 Jul 01, 2016 Jkt 238001 (Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Integrative Health, National Institutes of Health, HHS) Dated: June 28, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–15734 Filed 7–1–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Sleep Disorders Research Advisory Board. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Sleep Disorders Research Advisory Board. Date: August 18–19, 2016. Time: August 18, 2016, 1:00 p.m. to 5:00 p.m. Agenda: To discuss plans for the proposed revision of the NIH Sleep Disorders Research Plan, and potential directions for interagency coordination activities. Place: National Institutes of Health, Two Rockledge Center, Conference Room 9112/ 9116, 6701 Rockledge Drive, Bethesda, MD 20892–7952. Time: August 19, 2016, 8:00 a.m. to 3:00 p.m. Agenda: To discuss plans for the proposed revision of the NIH Sleep Disorders Research Plan, and potential directions for interagency coordination activities. Place: National Institutes of Health, Two Rockledge Center Conference Room 9112/ 9116, 6701 Rockledge Drive, Bethesda, MD 20892–7952. Contact Person: Michael J. Twery, Ph.D., Director, National Center on Sleep Disorders Research, Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Suite 10038, Bethesda, MD 20892–7952, 301– 435–0199, twerym@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, 93.840 Translation and Implementation Science for Heart, Lung, Blood Diseases, and Sleep Disorders, National Institutes of Health, HHS) PO 00000 Frm 00042 Fmt 4703 Sfmt 9990 43611 Dated: June 28, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–15732 Filed 7–1–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention; Advisory Committee; Drug Testing Advisory Board; Renewal Substance Abuse and Mental Health Services Administration, HHS. AGENCY: ACTION: Notice. The Substance Abuse and Mental Health Services Administration (SAMHSA) is announcing the renewal of SAMHSA’s Center for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board (DTAB). SUMMARY: FOR FURTHER INFORMATION CONTACT: Brian Makela, Division of Workplace Programs, CSAP, SAMHSA, 5600 Fishers Lane, Room 16N02B, Rockville, Maryland 20857, Telephone: 240–276– 2600, Fax: 240–276–2610, Email: brian.makela@ssamhsa.hhs.gov. The Center for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board (DTAB) is authorized by 42 U.S.C. 217a (Section 222 of the Public Health Service Act), as amended. The CSAP DTAB is governed by the provisions of the Federal Advisory Committee Act, as amended, 5 U.S.C., App., which sets forth standards for the formation and use of advisory committees. The CSAP DTAB provides advice to the Administrator, SAMHSA, based on an ongoing review of the direction, scope, balance, and emphasis of the Agency’s drug testing activities and the drug testing laboratory certification program. SUPPLEMENTARY INFORMATION: Summer King, Statistician, Substance Abuse and Mental Health Services Administration. [FR Doc. 2016–15815 Filed 7–1–16; 8:45 am] BILLING CODE 4162–20–P E:\FR\FM\05JYN1.SGM 05JYN1

Agencies

[Federal Register Volume 81, Number 128 (Tuesday, July 5, 2016)]
[Notices]
[Page 43611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-15815]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Center for Substance Abuse Prevention; Advisory Committee; Drug 
Testing Advisory Board; Renewal

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Substance Abuse and Mental Health Services Administration 
(SAMHSA) is announcing the renewal of SAMHSA's Center for Substance 
Abuse Prevention (CSAP) Drug Testing Advisory Board (DTAB).

FOR FURTHER INFORMATION CONTACT: Brian Makela, Division of Workplace 
Programs, CSAP, SAMHSA, 5600 Fishers Lane, Room 16N02B, Rockville, 
Maryland 20857, Telephone: 240-276-2600, Fax: 240-276-2610, Email: 
brian.makela@ssamhsa.hhs.gov.

SUPPLEMENTARY INFORMATION: The Center for Substance Abuse Prevention 
(CSAP) Drug Testing Advisory Board (DTAB) is authorized by 42 U.S.C. 
217a (Section 222 of the Public Health Service Act), as amended. The 
CSAP DTAB is governed by the provisions of the Federal Advisory 
Committee Act, as amended, 5 U.S.C., App., which sets forth standards 
for the formation and use of advisory committees.
    The CSAP DTAB provides advice to the Administrator, SAMHSA, based 
on an ongoing review of the direction, scope, balance, and emphasis of 
the Agency's drug testing activities and the drug testing laboratory 
certification program.

Summer King,
Statistician, Substance Abuse and Mental Health Services 
Administration.
[FR Doc. 2016-15815 Filed 7-1-16; 8:45 am]
 BILLING CODE 4162-20-P